Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Spontaneous Intracerebral Hemorrhage Due to Delta Storage Pool Disease in a Patient on a Serotonin-Norepinephrine Reuptake Inhibitor.

Leibetseder A, Wagner J, Tomasits J, Haring HP, Hutterer M, Trenkler J, von Oertzen TJ.

Front Neurol. 2019 Nov 26;10:1257. doi: 10.3389/fneur.2019.01257. eCollection 2019.

2.

Palliative care in glioma management.

Oberndorfer S, Hutterer M.

Curr Opin Oncol. 2019 Nov;31(6):548-553. doi: 10.1097/CCO.0000000000000584.

PMID:
31464760
3.

Increasing use of immunotherapy and prolonged survival among younger patients with primary CNS lymphoma: a population-based study.

Neuhauser M, Roetzer T, Oberndorfer S, Kitzwoegerer M, Payer F, Unterluggauer JJ, Haybaeck J, Stockhammer G, Iglseder S, Moser P, Thomé C, Stultschnig M, Wuertz F, Brandner-Kokalj T, Weis S, Bandke D, Pichler J, Hutterer M, Krenosz KJ, Boehm A, Mayrbaeurl B, Hager-Seifert A, Kaufmann H, Dumser M, Reiner-Concin A, Hoenigschnabl S, Kleindienst W, Hoffermann M, Dieckmann K, Kiesel B, Widhalm G, Marosi C, Jaeger U, Hainfellner A, Hackl M, Hainfellner JA, Preusser M, Woehrer A.

Acta Oncol. 2019 Jul;58(7):967-976. doi: 10.1080/0284186X.2019.1599137. Epub 2019 Apr 17.

PMID:
30994047
4.

Proseek single-plex protein assay kit system to detect sAxl and Gas6 in serological material of brain tumor patients.

Jaksch-Bogensperger H, Hammerschmid A, Aigner L, Trinka E, Gehwolf R, Ebner Y, Hutterer M, Couillard-Despres S.

Biotechnol Rep (Amst). 2018 Apr 17;18:e00252. doi: 10.1016/j.btre.2018.e00252. eCollection 2018 Jun.

5.

Chronophin regulates active vitamin B6 levels and transcriptomic features of glioblastoma cell lines cultured under non-adherent, serum-free conditions.

Schulze M, Hutterer M, Sabo A, Hoja S, Lorenz J, Rothhammer-Hampl T, Herold-Mende C, Floßbach L, Monoranu C, Riemenschneider MJ.

BMC Cancer. 2018 May 3;18(1):524. doi: 10.1186/s12885-018-4440-4.

6.

Isolated metastasis of an EGFR-L858R-mutated NSCLC of the meninges: the potential impact of CXCL12/CXCR4 axis in EGFRmut NSCLC in diagnosis, follow-up and treatment.

Lüke F, Blazquez R, Yamaci RF, Lu X, Pregler B, Hannus S, Menhart K, Hellwig D, Wester HJ, Kropf S, Heudobler D, Grosse J, Moosbauer J, Hutterer M, Hau P, Riemenschneider MJ, Bayerlová M, Bleckmann A, Polzer B, Beißbarth T, Klein CA, Pukrop T.

Oncotarget. 2018 Apr 10;9(27):18844-18857. doi: 10.18632/oncotarget.24787. eCollection 2018 Apr 10.

7.

Information needs and requirements in patients with brain tumours and their relatives.

Reinert C, Rathberger K, Klinkhammer-Schalke M, Kölbl O, Proescholdt M, Riemenschneider MJ, Schuierer G, Hutterer M, Gerken M, Hau P.

J Neurooncol. 2018 Jun;138(2):407-415. doi: 10.1007/s11060-018-2811-y. Epub 2018 Mar 7.

PMID:
29516343
8.

AIDS-Related Central Nervous System Toxoplasmosis With Increased 18F-Fluoroethyl-L-Tyrosine Amino Acid PET Uptake Due to LAT1/2 Expression of Inflammatory Cells.

Hutterer M, Bumes E, Riemenschneider MJ, Grosse J, Hellwig D, Galldiks N, Langen KJ, Hau P.

Clin Nucl Med. 2017 Dec;42(12):e506-e508. doi: 10.1097/RLU.0000000000001873.

PMID:
29076908
9.

Epileptic Activity Increases Cerebral Amino Acid Transport Assessed by 18F-Fluoroethyl-l-Tyrosine Amino Acid PET: A Potential Brain Tumor Mimic.

Hutterer M, Ebner Y, Riemenschneider MJ, Willuweit A, McCoy M, Egger B, Schröder M, Wendl C, Hellwig D, Grosse J, Menhart K, Proescholdt M, Fritsch B, Urbach H, Stockhammer G, Roelcke U, Galldiks N, Meyer PT, Langen KJ, Hau P, Trinka E.

J Nucl Med. 2017 Jan;58(1):129-137. doi: 10.2967/jnumed.116.176610. Epub 2016 Jul 28.

10.

Adaptive Immune Response to and Survival Effect of Temozolomide- and Valproic Acid-induced Autophagy in Glioblastoma.

Proske J, Walter L, Bumes E, Hutterer M, Vollmann-Zwerenz A, Eyüpoglu IY, Savaskan NE, Seliger C, Hau P, Uhl M.

Anticancer Res. 2016 Mar;36(3):899-905.

PMID:
26976976
11.

Adverse event grading following CTCAE v3.0 underestimates hypertensive side effects in patients with glioma treated with Bevacizumab.

Bumes E, Rzonsa S, Hutterer M, Proescholdt M, Bogdahn U, Riemenschneider MJ, Uhl M, Wendl C, Hau P.

J Neurooncol. 2016 Mar;127(1):191-200. doi: 10.1007/s11060-015-2031-7. Epub 2015 Dec 31.

PMID:
26721240
12.

Current standards and new concepts in MRI and PET response assessment of antiangiogenic therapies in high-grade glioma patients.

Hutterer M, Hattingen E, Palm C, Proescholdt MA, Hau P.

Neuro Oncol. 2015 Jun;17(6):784-800. doi: 10.1093/neuonc/nou322. Epub 2014 Dec 27. Review.

13.

Diagnosis of pseudoprogression in patients with glioblastoma using O-(2-[18F]fluoroethyl)-L-tyrosine PET.

Galldiks N, Dunkl V, Stoffels G, Hutterer M, Rapp M, Sabel M, Reifenberger G, Kebir S, Dorn F, Blau T, Herrlinger U, Hau P, Ruge MI, Kocher M, Goldbrunner R, Fink GR, Drzezga A, Schmidt M, Langen KJ.

Eur J Nucl Med Mol Imaging. 2015 Apr;42(5):685-95. doi: 10.1007/s00259-014-2959-4. Epub 2014 Nov 20.

PMID:
25411133
14.

Differential role of angiogenesis and tumour cell proliferation in brain metastases according to primary tumour type: analysis of 639 cases.

Berghoff AS, Ilhan-Mutlu A, Dinhof C, Magerle M, Hackl M, Widhalm G, Hainfellner JA, Dieckmann K, Pichler J, Hutterer M, Melchardt T, Bartsch R, Zielinski CC, Birner P, Preusser M.

Neuropathol Appl Neurobiol. 2015 Feb;41(2):e41-55. doi: 10.1111/nan.12185.

PMID:
25256708
15.

An intra-individual comparison of MRI, [18F]-FET and [18F]-FLT PET in patients with high-grade gliomas.

Nowosielski M, DiFranco MD, Putzer D, Seiz M, Recheis W, Jacobs AH, Stockhammer G, Hutterer M.

PLoS One. 2014 Apr 23;9(4):e95830. doi: 10.1371/journal.pone.0095830. eCollection 2014.

16.

Progression types after antiangiogenic therapy are related to outcome in recurrent glioblastoma.

Nowosielski M, Wiestler B, Goebel G, Hutterer M, Schlemmer HP, Stockhammer G, Wick W, Bendszus M, Radbruch A.

Neurology. 2014 May 13;82(19):1684-92. doi: 10.1212/WNL.0000000000000402. Epub 2014 Apr 11.

PMID:
24727314
17.

A single-arm phase II Austrian/German multicenter trial on continuous daily sunitinib in primary glioblastoma at first recurrence (SURGE 01-07).

Hutterer M, Nowosielski M, Haybaeck J, Embacher S, Stockhammer F, Gotwald T, Holzner B, Capper D, Preusser M, Marosi C, Oberndorfer S, Moik M, Buchroithner J, Seiz M, Tuettenberg J, Herrlinger U, Wick A, Vajkoczy P, Stockhammer G.

Neuro Oncol. 2014 Jan;16(1):92-102. doi: 10.1093/neuonc/not161. Epub 2013 Dec 4.

18.

Polyarteritis nodosa complicating multiple myeloma - a case report and review of the literature.

Hutterer M, Steurer M, Höftberger R, Hainfellner JA, Pircher A, Nowosielski M, Hau P, Löscher W, Gunsilius E, Berger T, Stockhammer G.

Clin Neuropathol. 2014 Mar-Apr;33(2):143-51. doi: 10.5414/NP300686.

PMID:
24220008
19.

Response to "reply to [18F]-fluoro-ethyl-L-tyrosine PET: a valuable diagnostic tool in neuro-oncology, but not all that glitters is glioma" by Hutterer et al.

Hutterer M, Nowosielski M, Putzer D, Fougère Cl, Virgolini IJ, Jacobs AH, Stockhammer G.

Neuro Oncol. 2013 Jul;15(7):814-5. doi: 10.1093/neuonc/not081. Epub 2013 Jun 19. No abstract available.

20.

Preoperative diffusion-weighted imaging of single brain metastases correlates with patient survival times.

Berghoff AS, Spanberger T, Ilhan-Mutlu A, Magerle M, Hutterer M, Woehrer A, Hackl M, Widhalm G, Dieckmann K, Marosi C, Birner P, Prayer D, Preusser M.

PLoS One. 2013;8(2):e55464. doi: 10.1371/journal.pone.0055464. Epub 2013 Feb 5.

21.

[18F]-fluoro-ethyl-L-tyrosine PET: a valuable diagnostic tool in neuro-oncology, but not all that glitters is glioma.

Hutterer M, Nowosielski M, Putzer D, Jansen NL, Seiz M, Schocke M, McCoy M, Göbel G, la Fougère C, Virgolini IJ, Trinka E, Jacobs AH, Stockhammer G.

Neuro Oncol. 2013 Mar;15(3):341-51. doi: 10.1093/neuonc/nos300. Epub 2013 Jan 17.

22.

Extent of peritumoral brain edema correlates with prognosis, tumoral growth pattern, HIF1a expression and angiogenic activity in patients with single brain metastases.

Spanberger T, Berghoff AS, Dinhof C, Ilhan-Mutlu A, Magerle M, Hutterer M, Pichler J, Wöhrer A, Hackl M, Widhalm G, Hainfellner JA, Dieckmann K, Marosi C, Birner P, Prayer D, Preusser M.

Clin Exp Metastasis. 2013 Apr;30(4):357-68. doi: 10.1007/s10585-012-9542-9. Epub 2012 Oct 17.

PMID:
23076770
23.

Isolated leptomeningeal infiltration of a primary CNS B-cell lymphoma diagnosed by flow cytometry and confirmed by necropsy.

Broussalis E, Hutterer M, Oppermann K, Wipfler P, Pilz G, Harrer A, Haschke-Becher E, Golaszewski S, Schönauer U, Weis S, Killer-Oberpfalzer M, Mc Coy M, Trinka E, Kraus J.

Acta Neurol Scand. 2012 Sep;126(3):e11-6. doi: 10.1111/j.1600-0404.2011.01630.x. Epub 2011 Dec 26.

PMID:
22211863
24.

O-(2-18F-fluoroethyl)-L-tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent high-grade glioma.

Hutterer M, Nowosielski M, Putzer D, Waitz D, Tinkhauser G, Kostron H, Muigg A, Virgolini IJ, Staffen W, Trinka E, Gotwald T, Jacobs AH, Stockhammer G.

J Nucl Med. 2011 Jun;52(6):856-64. doi: 10.2967/jnumed.110.086645.

25.

[Patient reported outcome monitoring using a tablet PC is suitable for measuring quality of life in patients with gliomas].

Holzner B, Schauer-Maurer G, Stockhammer G, Muigg A, Hutterer M, Giesinger J.

Wien Med Wochenschr. 2011 Jan;161(1-2):6-12. doi: 10.1007/s10354-011-0872-z. German.

PMID:
21312093
26.

ADC histograms predict response to anti-angiogenic therapy in patients with recurrent high-grade glioma.

Nowosielski M, Recheis W, Goebel G, Güler O, Tinkhauser G, Kostron H, Schocke M, Gotwald T, Stockhammer G, Hutterer M.

Neuroradiology. 2011 Apr;53(4):291-302. doi: 10.1007/s00234-010-0808-0. Epub 2010 Dec 2.

27.

Implementation of computer-based quality-of-life monitoring in brain tumor outpatients in routine clinical practice.

Erharter A, Giesinger J, Kemmler G, Schauer-Maurer G, Stockhammer G, Muigg A, Hutterer M, Rumpold G, Sperner-Unterweger B, Holzner B.

J Pain Symptom Manage. 2010 Feb;39(2):219-29. doi: 10.1016/j.jpainsymman.2009.06.015.

28.

Disease stabilization of progressive olfactory neuroblastoma (esthesioneuroblastoma) under treatment with sunitinib mesylate.

Preusser M, Hutterer M, Sohm M, Koperek O, Elandt K, Dieckmann K, Prayer D, Marosi C.

J Neurooncol. 2010 Apr;97(2):305-8. doi: 10.1007/s11060-009-0027-x. Epub 2009 Oct 10.

PMID:
19820899
29.

Do neurooncological patients and their significant others agree on quality of life ratings?

Giesinger JM, Golser M, Erharter A, Kemmler G, Schauer-Maurer G, Stockhammer G, Muigg A, Hutterer M, Rumpold G, Holzner B.

Health Qual Life Outcomes. 2009 Oct 9;7:87. doi: 10.1186/1477-7525-7-87.

30.

Elderly patients with glioblastoma multiforme--an underestimated subpopulation?

Hutterer M.

Neuroepidemiology. 2009;33(1):23-4. doi: 10.1159/000210018. Epub 2009 Mar 27. Review. No abstract available.

31.

The impact of the DNA-repair gene MGMT in malignant gliomas.

Hutterer M.

Neuroepidemiology. 2009;32(1):30-1. doi: 10.1159/000170089. Epub 2008 Nov 8. No abstract available.

32.

HER3 is a determinant for poor prognosis in melanoma.

Reschke M, Mihic-Probst D, van der Horst EH, Knyazev P, Wild PJ, Hutterer M, Meyer S, Dummer R, Moch H, Ullrich A.

Clin Cancer Res. 2008 Aug 15;14(16):5188-97. doi: 10.1158/1078-0432.CCR-08-0186.

33.

Axl and growth arrest-specific gene 6 are frequently overexpressed in human gliomas and predict poor prognosis in patients with glioblastoma multiforme.

Hutterer M, Knyazev P, Abate A, Reschke M, Maier H, Stefanova N, Knyazeva T, Barbieri V, Reindl M, Muigg A, Kostron H, Stockhammer G, Ullrich A.

Clin Cancer Res. 2008 Jan 1;14(1):130-8. doi: 10.1158/1078-0432.CCR-07-0862.

34.

Molecular therapies for malignant glioma.

Hutterer M, Gunsilius E, Stockhammer G.

Wien Med Wochenschr. 2006 Jun;156(11-12):351-63. Review.

PMID:
16944367

Supplemental Content

Loading ...
Support Center